Theralase Technologies Inc.

600 Alden Road
Suite 101
Markham
Ontario
L3R 0E7
Canada

Tel: 905-947-8455
Fax: 905-947-8550

Show jobs for this employer

65 articles with Theralase Technologies Inc.

  • Theralase® Technologies Inc. has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements, which provides financial information on the previous fiscal quarter and the quarterly Newsletter which provides an interim clinical data analysis on the Phase II Non-Muscle Invasive Bladder Cancer clinical study.

  • Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations, announced the following leadership reorganization:

  • Theralase® Technologies Inc. has released the Company’s unaudited Q22021 condensed interim consolidated financial statements and Quarterly Newsletter which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

  • Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer (“CEO”), Shawn Shirazi effective August 20, 2021.

  • Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy technologies intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life announced the launch of the seventh US-based Clinical Study Site ; specifically, the University of Chicago Medicine.

  • Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its unaudited Q12021 condensed interim consolidated financial statements.

  • Theralase Technologies Inc. a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2020 financial statements.

  • Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company's Quarterly Newsletter which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

  • Theralase® Technologies Inc. announced that it has executed a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine.

  • Theralase Technologies Inc. announced today the launch of the Theralase® Anti-Cancer Therapy ("ACT") research centre located within the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network ("UHN"), Toronto.

  • Theralase® Technologies Inc. announced that Urology San Antonio has received site Institutional Review Board approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients with Bacillus Calmette Guerin-Unresponsive Carcinoma In-Situ or who are intolerant to BCG Therapy.

  • Theralase Technologies Inc. announced today that University of Wisconsin Health-Madison ("UWH") has received site Institutional Review Board ("IRB") approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer

  • Theralase Technologies Inc. has released the Company Quarterly Newsletter.

  • Theralase Technologies Inc.announced today that Carolina Urologic Research Center ("CURC") has received site Institutional Review Board ("IRB") approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study to enroll and treat patients with Bacillus Calmette Guerin("BCG")-Unresponsive Carcinoma In-Situ

  • Theralase Technologies Inc. announced today that MidLantic Urology ("MU") has received site Institutional Review Board ("IRB") approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study

  • Theralase Technologies Inc. ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations used to destroy various cancers, bacteria and viruses safely and effectively is pleased to announce that the Company has expanded its Intellectual property portfolio

  • Theralase® Technologies Inc. announced that Urology Associates P.C. has received site Institutional Review Board approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients with Bacillus Calmette Guerin-Unresponsive Carcinoma In-Situ or are intolerant to BCG Therapy.

  • Theralase Technologies Inc. announced today that Virginia Urology ("VU") has received site Institutional Review Board ("IRB") approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study to enroll and treat patients with Bacillus Calmette Guerin("BCG")-Unresponsive Carcinoma In-Situ ("CIS") or are intolerant to BCG Therapy ("Study II").

  • Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 4,095,157 share purchase warrants, all of which are exercisable at $0.50 per share.

  • Theralase® Technologies Inc. announced that the University of British Columbia Review Ethics Board has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients who present with Carcinoma In-Situ and who are considered Bacillus Calmette Guerin-Unresponsive or are intolerant to BCG Therapy.